Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells

Scott Best(Oregon Health & Science University), Alexey V. Danilov(City of Hope), Tingting Liu(Oregon Health & Science University), Allison Berger(Takeda (United States)), Vi Lam(Oregon Health & Science University), Nathan D. Pennock(Oregon Health & Science University), Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Susan Murray(Oregon Health & Science University), Evan Lind(Oregon Health & Science University), Olga V. Danilova(Oregon Health & Science University), Nur Bruss(Oregon Health & Science University)
Leukemia
March 16, 2020
10.1038/s41375-020-0794-0
Cited by 38

Related Papers

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
|Nature|2009|2k
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma
|Blood|2010|323
Immune Checkpoint Inhibitors in Organ Transplant Patients
|Journal of Immunotherapy|2017|150
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia
|JACC CardioOncology|2023|107
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib
|Cancer|2018|86